Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06797245 · ClinicalTrials.gov registry record · NA
APPROVE Trial: Evaluating a Prescription Digital Therapeutic for Treatment of OAB in Women
A NA study of Nocturia and Overactive Bladder (OAB), sponsored by Medstar Health Research Institute.
- Recruiting
- Registry status
- NA
- Development phase
- 596
- Enrollment target
- 10
- Study locations
NCT06797245 is a NA study of Nocturia and Overactive Bladder (OAB) that is actively recruiting participants, run by Medstar Health Research Institute. The registered enrollment target is 596 participants, above the 250-participant average among 9 other Nocturia trials with a reported enrollment target (138% higher). The trial reports 10 study locations across 10 states.
The verdict
NCT06797245, a NA study of Nocturia and Overactive Bladder (OAB), is actively recruiting participants, sponsored by Medstar Health Research Institute.
- RECRUITING
- Registry status
- NA
- Development phase
- 596 participants
- Enrollment target
- 10
- Study locations
Study Summary
The APPROVE trial is a multi-centered, randomized controlled trial designed to assess differences in symptom improvement, quality of life, bladder symptoms, satisfaction with treatment and continued treatment efficacy in women with overactive bladder (OAB) randomized to a prescription digital therapeutic (PDTx) app called RiSolve compared to standard behavioral education (handouts).
Conditions Studied
Interventions
- DEVICE RiSolve App
- BEHAVIORAL AUGS Patient Handouts
Study Locations (10)
Alabama
- University of Alabama at Birmingham - Birmingham
California
- Stanford University - Palo Alto
District of Columbia
- MedStar Health - Washington D.C.
Illinois
- University of Chicago - Chicago
Massachusetts
- Curavit - Boston
North Carolina
- Atrium Health Wake Forest Baptist - Winston-Salem
Pennsylvania
- Allegheny Health - Pittsburgh
South Carolina
- Medical University of South Carolina Health - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 596 participants |
| Start Date | 2025-03-17 |
| Est. Completion | 2028-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06797245
The ClinicalTrials.gov registry entry for NCT06797245 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 596 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 250-participant average among 9 other Nocturia trials with a reported enrollment target (138% higher). The listed sponsor is Medstar Health Research Institute, which has 115 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Nocturia appearing as the primary indexed condition, and to 2 interventions - of which RiSolve App is the first listed.
NCT06797245 reports 10 study locations spanning 10 distinct geographic areas - top geographies include Alabama, California, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT06797245 about?
NCT06797245 is a clinical study titled "APPROVE Trial: Evaluating a Prescription Digital Therapeutic for Treatment of OAB in Women". The APPROVE trial is a multi-centered, randomized controlled trial designed to assess differences in symptom improvement, quality of life, bladder symptoms, satisfaction with treatment and continued treatment efficacy in women with overactive bladder (OAB) randomized to a prescription digital therap...
What is the current status of trial NCT06797245?
This trial is currently recruiting. It is a NA study. The enrollment target is 596 participants. The study started on 2025-03-17. Estimated completion is 2028-07.
What conditions does trial NCT06797245 study?
This clinical trial studies the following conditions: Nocturia, Overactive Bladder (OAB), Urinary Frequency, Urinary Urgency, Urinary Urge Incontinence (UUI).
What interventions are being tested in trial NCT06797245?
The interventions under investigation include: RiSolve App (DEVICE), AUGS Patient Handouts (BEHAVIORAL).
Who is sponsoring clinical trial NCT06797245?
This trial is sponsored by Medstar Health Research Institute, which has 115 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06797245 being conducted?
This trial has 10 study locations across Alabama, California, District of Columbia, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nocturia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Mandibular Advancement Device and Changes in Nocturia
RECRUITING · NA
-
Multi-center Trial to Improve Nocturia and Sleep in Older Adults
RECRUITING · NA
-
Post-procedural Pain Associated With 5 Versus 20 Intravesical Injections of Onabotulinumtoxin A
RECRUITING · Phase 4
-
Effect of Behavioral Sleep Intervention on Lower Urinary Tract Symptoms in Older Women
RECRUITING · Phase 4
-
Efficacy and Safety of Desmopressin Melt for the Treatment of Nocturia
COMPLETED · Phase 3
-
Study Investigating the Impact Burden of Nocturia Using the Nocturia Impact Diary
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.